Study on the clinical efficacy and safety of different platinum-based chemotherapy regimens combined with slulizumab as first-line treatment for extensive-stage small cell lung cancer
Xi Yuansheng
Chen Yan
Luo Xinting
Yang Feihu
Wang Hongbing
Abstract：Objective To investigate the clinical efficacy and safety of different platinum-based chemotherapy regimens combined with slulizumab as first-line treatment for extensive-stage small cell lung cancer(ES-SCLC).Methods A total of 118 patients with ES-SCLC admitted to the Affiliated Hospital of Xuzhou Medical University from October 1,2022 to September 30,2024 were retrospectively selected.According to the different chemothera-py regimens,they were divided into lobaplatin group(65 cases)and carboplatin group(53 cases).The patients in the lobaplatin group were treated with lobaplatin combined with etoposide and slulizumab,and the patients in the carboplatin group were treated with carboplatin combined with etoposide and slulizumab,every 21 days as a cycle.The patients in the two groups were treated for 4 cycles.The general data,short-term efficacy,long-term efficacy,and adverse reactions of the two groups were compared.Results There were no significant differences in gender,age,smoking history,Eastern Cooperative Oncology Group performance status scale score,liver metastasis,brain metastasis,bone metastasis,adrenal metastasis,and thoracic radiotherapy between the two groups(all P＞0.05).There was no significant difference in objective response rate and disease control rate between lobaplatin group and carboplatin group[64.6％(42/65)vs 69.8％(37/53),83.1％(54/65)vs 88.7％(47/53)](x2=0.356,P=0.551;x2=0.743,P=0.389).There were no significant differences in progression-free survival and overall survival between the two groups(both P＞0.05).The incidences of nausea and vomiting and allergic reactions in the lobaplatin group were lower than those in the carboplatin group(both P＜0.05).Conclusion Lobaplatin combined with etoposide and slulizumab and carboplatin combined with etoposide and slulizumab are effective in the first-line treatment of ES-SCLC.The incidence of nausea and vomiting and allergic reactions in the lobaplatin group is lower than that in the carboplatin group.
Keywords：Extensive-stage small cell lung cancerLobaplatinCarboplatinSlulizumabClinical efficacy
Publication Date：2025-10-18
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 1483-1487 )